Autism diagnoses are climbing fast—1 in 36 kids today, a far cry from 1 in 10,000 in 1970. As a physician, I’ve seen families wrestle with this rise, caught in a maze of science, skepticism, and shifting norms. This Independence Day, Fourth of July, I’m reflecting on autism’s tangled roots, along with a cautionary tale: the Continental Army used cowpox inoculation—a proto-vaccine—to fend off smallpox, helping secure our independence. “These injections helped our troops survive harsh winters, cheek by jowl, to outmaneuver the British”. That history grounds us: vaccines saved lives, but questioning their role in autism isn’t about rejecting progress. It’s about truth. Here’s a roadmap to understanding autism’s surge, blending biology, culture, and environmental factors, with a nod to how society shapes our perceptions.
Autism isn’t one-size-fits-all. It’s a spectrum, from kids who can’t speak to high achievers like Elon Musk, whose focus sparks genius. “Autism includes Elon Musk. Have we simply pathologized eccentricity and (occasionally) genius?” I wrote. Over 100 genetic variants tweak brain wiring—synaptic glitches or frontal lobe overgrowth—but genes aren’t the whole story. Identical twins, who share DNA, often diverge: one becomes autistic, while the other does not. Heritability ranges from 38% to 87%, with environmental cues acting like a conductor. “Think of the genome as a musical score: the notes don’t change, but depending on who’s conducting, it can sound like classical or rock.” Prenatal factors like older parents or toxins, and postnatal triggers, could flip the switch. We need studies to pinpoint these, not just shrug and say, “It’s genetic.”
The label has ballooned. In 1911, “autism” meant schizophrenic hallucinations. By 1980, it was a developmental disorder; by 1994, it swept in milder cases—smart kids with social quirks. “As the term ‘mental retardation’ gave way to ‘intellectual disability,’ some cases were reclassified under autism’s expanding umbrella.” Deinstitutionalization, spurred by JFK’s 1961 panel and drugs like Thorazine, emptied asylums. “The decline of U.S. mental institutions may have played an indirect role in the rise of autism diagnoses—not by causing autism, but by reshaping how society categorized and responded to developmental differences.” Early screening at 18 months catches more, but are we seeing autism or naming it? In Africa, with a billion people, autism barely registers. Is it underdiagnosed, or does a life of manual labor—digging rare earths, not coding—make quirks less noticeable? In the 1970s, in Uganda, back pain wasn’t a diagnosis; there was no system to reward it. Context shapes labels.
Money drives diagnoses, too. Schools receive funds for autism labels; families tap into SSI benefits, which increased by 154% from 2004 to 2014. “Financial incentives for special education, therapies, and clinical services create perverse pressures for overdiagnosis.” In states like Michigan, rates spiked with rewards, then fell without them. Sweden shows more diagnoses, milder symptoms—quirks, not crises. “Are we seeing an epidemic of biology, or semantics?” California’s caseload has quadrupled since 2011. Is it bureaucracy or something in the air?
Environmental factors raise questions I’ll explore more in future segments—Fluoride, aluminum, glyphosate, Wi-Fi—speculated culprits with thin evidence. Thimerosal’s out of vaccines, but aluminum adjuvants, meant to spark immunity, might, in rare cases, overstimulate a prone brain. Animal studies suggest inflammation risks. Prenatal acetaminophen or ultrasound overuse could play a role, too. “Autism likely starts in the womb, tied to embryologic neurodevelopment,” but postnatal triggers like immune stress can’t be ruled out. We need rigorous studies, not dismissals.
Vaccines are the loudest debate. Smallpox inoculation saved the Continental Army, but today’s schedule—7 diseases in 1986, 16 now—stirs distrust. MMR shows no clear autism link in big studies, yet skepticism persists. “In autism, too much ‘gas’ (excitation) and not enough ‘brake’ (calming),” could explain why some kids react strongly to immune triggers. Why give MMR at 12 months, when boys—diagnosed 4 to 1—face higher odds? Delaying shots or tailoring schedules isn’t anti-vaccine; it’s sense. We need transparent research.
Society’s shifted, too. Boys, wired for risk, clash with schools favoring conformity. “Instead of a city that developed organically, it’s more like a centrally planned boomtown—roads laid down too fast, towers built in haste.” Recess is gone; zero-tolerance policies punish energy. In simpler times, intensity found outlets—farming, crafting. Now it’s a diagnosis. Africa’s low autism rates, or the Amish’s, suggest culture matters: less tech, fewer shots, tighter communities. Autism’s rise tracks spikes in opioids, divorce, and homelessness. Something’s changing.
This is about questions, not answers. “Autism diagnoses are surging, touching countless families, yet the reasons remain elusive, fueling debate and confusion.” We need cross-cultural data, no taboo topics. Like those soldiers braving smallpox for freedom, we owe kids courage, not dogma.
[PS, a second show, upcoming, on this topic will cover the environmental risks contemplated for the autism surge, along with the concept of “regression”]
Discover more from Randy Bock MD PC
Subscribe to get the latest posts sent to your email.
